News
Public · Published
Wells Fargo maintains Incyte at Equal-Weight, lowers price target to $127 from $128
Wells Fargo kept its Equal-Weight rating on Incyte and cut its price target to $127 from $128, a 0.8% decrease. The new target implies 8.7% upside from the October 29 close of $116.80.
Published:
Updated:
What happened
Wells Fargo kept its Equal-Weight rating on Incyte and cut its price target to $127 from $128, a 0.8% decrease. The new target implies 8.7% upside from the October 29 close of $116.80.
Confirmed
Global impact / market context
A lower price target means the analyst expects slightly less upside for Incyte shares, which can reduce the appeal of holding the stock and may prompt some investors to trim positions or wait for clearer signals before buying.
Analyst inference
Recent analyst targets on Incyte range from $117 to $144 across five notes in 30 days, showing divided views. Ratings run from Sector Perform, which means roughly market-level expectations, to Overweight and Outperform, which mean expected outperformance.
Analyst inference
What to watch
- Wells Fargo's $127 target sits within the recent $117 to $144 range from five analyst notes published over the past 30 days. Confirmed
- Watch whether other analysts change their Incyte price targets or ratings after Wells Fargo's small cut, since several firms issued notes around October 30. Proposed
- Track Incyte's share price against the $116.80 close to see whether the implied 8.7% upside holds or fades as new analyst views arrive. Analyst inference
Evidence
- Original source link unavailable